Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Third Harmonic Bio Says Data From Its Phase 1 Trial Of THB335 In Healthy Volunteers Supports The Advancement Into A Phase 2 Trial In Chronic Spontaneous Urticaria; The Company Is Initiating A Strategic Review Process To Run In Parallel With Phase 2 Readiness Activities To Identify Opportunities To Maximize Shareholder Value

Author: Benzinga Newsdesk | February 11, 2025 08:09am

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)
Company initiating process to leverage balance sheet strength to maximize shareholder value
Cash and cash equivalents of approximately $285 million as of December 31, 2024 (unaudited)

Posted In: THRD